Clinical Trials Directory

Trials / Unknown

UnknownNCT02290548

Effect of High-flow Nasal Oxygen on Extubation Outcome

Effect of High-flow Nasal Oxygen vs Standard Oxygen Therapy on Extubation Outcome With High Risk of Extubation Failure in Medical ICU Patients

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
400 (estimated)
Sponsor
Mackay Memorial Hospital · Academic / Other
Sex
All
Age
18 Years – 95 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether high flow nasal cannula is effective in lowering the reintubation rate after extubation for high risk patients in medical intensive care unit

Detailed description

The study hypothesis is that Optiflow may reduce the extubation failure rate for high risk patients in medical intensive care unit.In the intervention group, patients fulfilling inclusion criteria and not presenting any of the exclusion criteria will receive high-flow nasal cannula (Optiflow Airvo2, Fisher \& Paykel Healthcare Ltd., New Zealand) after extubation. The oxygen concentration (FiO2) will be set to reach an oxygenation target similar to control patients (see below), while the gas flow rate will be set at 50 L/min.In the control group, patients fulfilling inclusion criteria and not presenting any of the exclusion criteria will receive standard oxygen therapy including nasal cannula or oxygen mask after extubation. The FiO2 will be set to obtain a arterial oxygen saturation (SpO2) between 92% and 98% (or between 88% and 95% in hypercapnic patients). NIPPV or intubation will be applied in both group if respiratory distress noted. High flow nasal cannula will be tried before NIPPV or intubation in the control group patients.

Conditions

Interventions

TypeNameDescription
DEVICEhigh flow nasal cannulaHigh flow nasal cannula used in postextubation patients

Timeline

Start date
2014-12-01
Primary completion
2016-09-01
Completion
2016-10-01
First posted
2014-11-14
Last updated
2014-12-15

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT02290548. Inclusion in this directory is not an endorsement.